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DIFFERENT FROM ALL OTHER
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Anthropological Perspectives on Genetic Susceptibility
Testing for Breast Cancer
Nancy Press, Ph.D.!
Wylie Burke, M.D., Ph.D.t
Sharon Durfy, Ph.D."
IN 1994, WHEN THE FIRST GENE was found whose
mutations predispose some women to breast and ovarian can-
cer, researchers stressed that mutations in this BRCA1 gene
probably accounted for no more than five percent of all breast
cancers' and that these were cancers in women from very
high-risk families.2 Yet, the idea of population-based testing is
implicit in much of the media coverage of this discovery and
has been kept alive by reports that commercial enterprises are
gearing up to make testing available in the near future directly
to women or through their primary care providers Policy
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1. See Yoshio Miki et al., A Strong Candidate for the Breast and Ovarian Cancer Sus-
ceptibility Gene BRCA1, 266 SCIENCE 66, 66 (1994) (explaining the positional cloning methods
used to discover the BRCA1 gene).
2. See generally D.F. Easton et al., Genetic Linkage Analysis in Familial Breast and
Ovarian Cancer: Results from 214 Families, 52 AM. J. HUM. GENEICS 678, 678 (1993)
(analyzing the inherited component of breast and ovarian cancer in a study of families); Kevin
Davies, Further Enigmatic Variations, 378 NATURE 762,762 (1995).
3. See generally Natalie Angier, Scientists Identify a Mutant Gene Tied to Hereditary
Breast Cancer, N.Y. TIMEs, Sept. 15, 1994, at Al (announcing the discovery of BRCAI gene);
Elyse Tanouye, Gene Testing for Cancer to be Widely Available, Raising Thorny Questions,
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statements in response to the idea of broad-based testing have
been issued by many professional and consumer groups.4
These statements raise concerns about unanswered scientific
questions, such as the penetrance and incidence of the various
BRCA1 mutations and the efficacy of potential prevention and
detection options following a positive test result. They also
point to the need to thoroughly investigate the psychosocial
effects of testing. These may include anxiety, depression, fami-
ly disruption following both positive and negative results, and
potential employment and insurance discrimination. Some
authors have posited dangers of a more global nature, including
stigmatization, the potential of genetic information to seem
unalterable and inevitable, and the difficulty physicians and test
consumers may have in understanding the probabilistic nature
of genetic test results.5 While considerable research is current-
ly underway to address many of these issues,6 most of the
WALL ST. J., Dec. 14, 1993, at B1 (describing commercial efforts to make BRCAI testing
available to the public). Cf Jean Marx, Gene Defect Identified in Common Hereditary Colon
Cancer, 262 SCIENCE 1645, 1645 (1993) (discussing the discovery of the gene that causes an
inherited form of colon cancer and genetic screening for susceptible individuals in the population
at large).
4. See American Society of Clinical Oncology, Statement of the American Society of
Clinical Oncology: Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL ONCOLOGY 1730,
1730-36 (1996) (setting forth one professional organization's policy statement regarding genetic
testing for cancer susceptibility); Hereditary Susceptibility Working Group, National Action Plan
on Breast Cancer, Commentary on the ASCO Statement on Genetic Testing for Cancer
Susceptibility, 14 J. CLINICAL ONCOLOGY 1738, 1738 (1996) (documenting concerns that genetic
testing without the requisite scientific knowledge makes clinical use of tests premature); Neil A.
Holtzman, From Discovery to Delivery: Are We Ready to Screen for Inherited Susceptibility to
Cancer?, ONCOLOGY (forthcoming 1996); Ruth Hubbard & R.C. Lewontin, Pitfalls of Genetic
Testing, 334 NEW ENG. J. MED. 1192, 1193 (1996) (stating opposition of two groups to testing
outside of controlled clinical trials); Francis S. Collins, BRCAl-Lots of Mutations, Lots of Di-
lemmas, 334 NEw ENG. J. MED. 186, 187-88 (1996) (noting that several organizations are calling
for testing to remain a research activity due to uncertainties), National Advisory Council for
Human Genome Research, Statement on Use of DNA Testing for Presymptomatic Identification of
Cancer Risk, 271 JAMA 785, 785 (1994) (stating that many questions must be addressed prior to
making broad-based genetic testing available).
5. See Barbara Koenig, Gene Tests: What You Know Can Hurt You, N.Y. TIMES, Apr. 6,
1991, at A23 (suggesting reasons why extreme caution should be used when testing for breast
cancer genes in women).
6. The most notable set of research projects into the psychosocial and ethical implications
of genetic susceptibility testing for cancer are fifteen projects being funded by a four-agency, NIH
Cancer Genetics Studies Consortium. These projects are distributed throughout the United States
and Canada. The majority are investigating the psychosocial impact of undergoing genetic testing
for cancer risk, some among ethnically diverse populations. A small number of studies are also
investigating issues such as the ideal informed consent process for genetic testing and physician,
as well as test consumer attitudes.
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policy statements counsel caution and recommend that genetic
susceptibility testing for breast cancer remain within research
protocols for the present time.
However, the concern that population-based mutation
testing might precipitously become a reality increased when it
was reported in 1995 that one BRCA1 mutation, described as
185delAG, was particularly common among women of
Ashkenazi-Jewish descent Results from the first, small-scale
studies indicate that Ashkenazi-Jewish women, those of East-
ern-European descent who comprise close to ninety-five per-
cent of the Jewish population in the United States, might have
rates of deleterious mutations in the BRCA1 gene several times
greater than other women.8 In addition, it has been suggested
that the 185delAG mutation is particularly likely to be a cause
of breast cancer diagnosed in young Jewish women.9 Further-
more, having even a mild family history of breast cancer might
particularly predispose Jewish women to breast cancer.10
None of these findings indicate that a Jewish woman is
necessarily more likely to get breast cancer than a non-Jewish
woman. Yet, when a commercial biotechnology firm an-
nounced that it was interested in offering 185delAG testing to
all interested Ashkenazi-Jewish women," concern was ex-
pressed that women would not understand that this offer was
based primarily on the greater technical feasibility and reason-
able costs involved in looking for only one mutation. It was
7. See David E. Golgar & Philip R. Reilly, A Common BRCA1 Mutation in the
Ashkenazim, 11 NATURE GENETIcs 113, 113-14 (1995) (describing the implications of a survey
which found unexpectedly high frequency of the 185delAG BRCA1 mutation in Ashkenazi-
Jewish women).
8. See Jeffery P. Struewing et al., The Carrier Frequency of the BRCA1 185delAG
Mutation is Approximately I Percent in Ashkenazi Jewish Individuals, 11 NATURE GENETICS 198,
198 (1995) (noting that this group's test study of DNA determined a 0.9% frequency of the
185delAG mutation in Ashkenazi individuals and none in the reference group).
9. See Michael G. FitzGerald et al., Germ-line BRCAI Mutations in Jewish and Non-
Jewish Women with Early-Onset Breast Cancer, 334 NEw ENG. J. MED. 143, 148-49 (1996) (de-
scribing research methodology and findings in a study exploring the incidence of the 185delAG
mutation in Jewish and non-Jewish women and the correlation with early-onset breast disease).
10. See Kathleen M. Egan et al., Jewish Religion and Risk of Breast Cancer, 347 LANCEr
1645, 1646 (1996) (finding a correlation of family history of breast cancer to the disposition
towards cancer in Jewish women).
11. See Gina Kolata, Breaking Ranks, Lab Offers Test to Assess Risk of Cancer, N.Y.
TIMES, Apr. 1, 1996, at Al (identifying a commercial firm that is making the BRCA1 test
available and exploring the rationale for the decision).
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feared that women might instead assume that they were at
particular risk for breast cancer on the basis of their ethnicity
alone, and therefore, they should be tested. Although it has
been pointed out by many concerned parties that almost all the
unanswered questions that pertain to BRCA1 testing in general
remain relevant to the case of 185delAG testing, a public dia-
logue rapidly emerged which suggests that to refuse testing to
any Jewish woman who wants it is paternalism rather than
good public policy. 2
Presently, only one company is offering 185delAG testing.
However, concerns about the possibility of a large demand for
185delAG testing stem from a belief that Jewish women will
be different from other women in their response to an offer of
testing. Specifically, their enthusiasm and demand for testing
will be much greater. This belief is based on a particular set of
assumptions about Jewish culture. First, that Jewish culture
places particular value on science and medicine. Second, that
there is a great sense of community among Jews and that,
linked with the positive predisposition to science, this will
translate into a perceived responsibility to take part in any sort
of research endeavor that has the potential to help the commu-
nity. A corollary assumption is that in Jewish culture scientific
knowledge is always thought to be useful. Finally, there is an
assumption that Jewish doctrine, 3 and more generalized cul-
tural leanings, coalesce to create a particular attentiveness
among Jews to issues of health. The fear is that these aspects
of Jewish culture will combine to make this group particularly
vulnerable to any offer of genetic susceptibility testing.
We would argue instead that this set of assumptions about
Jewish culture can be completely accurate without necessarily
indicating that Jewish women will react differently from other
12. See Joseph D. Shulman et al., Genetic Predisposition Testing for Breast Cancer,
CANCER J. SC. AM. (forthcoming Sept. 1996); Walter Gilbert & Barbara Biesecker, Pro Con:
Should the Breast Cancer Gene Test be Available to Any Woman Who Wants It?, HEALTH July-
Aug. 1996, at 32 (offering a breakdown of the reasons for and against offering testing for the
BRCA1 gene); Wylie Burke et al., First Do No Harm Applies to Cancer Susceptibility Testing
Too, CANCER J. Sci. AM. (forthcoming Sept. 1996).
13. See generally Elliot N. Dorff, Jewish Theological and Moral Reflections on Genetic
Screening: The Case of BRCA1, 7 HEALTH MATRIX 65 (1997); Fred Rosner, Principles of
Practice Concerning the Jewish Patient, 11 J. GEN. INTERNAL MED. 486, 486 (1996) (relating the
relevance of Judaism to the Jewish patient).
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women with regard to interest in genetic testing for breast can-
cer risk. In fact, when news of the 185delAG mutation was
first announced, there was an assumption at the National Insti-
tutes of Health, (NIH) and elsewhere, that a flood of requests
for testing would follow. This did not, however, prove to be
the case.' 4 It is true that the synagogue-affiliated Jewish com-
munity (about fifty percent of Jews) in the Baltimore-Washing-
ton area has been extremely cooperative with those conducting
epidemiological studies on the occurrence of the 185delAG
mutation in a population-based sample. 5 This may be ex-
plained by a positive view among Jews about the value of
scientific research. Furthermore, the Jewish community in this
area had a positive experience with Tay-Sachs researchers in
the 1970s. But whatever factors explain Jewish cooperation
with this research effort, one cannot generalize from this sup-
port for an epidemiological study demand by the average Jew-
ish woman for susceptibility testing.
In fact, we would suggest that at the current time there is
simply a lack of data on which to base projections about the
attitudes and interest of most women, Jewish or non-Jewish, in
susceptibility testing. The majority of research studies currently
underway to address these issues involve women in very high-
risk families. Many of these families were participants in the
long-term research which helped locate the BRCA1 gene and
its mutations. Families selected to participate in these "gene-
hunting" studies were atypical in the particularly heavy burden
of disease they carried through several generations - a burden
which may also have motivated their participation as research
subjects. This very special history limits the generalization of
data from these studies to other women. Similarly, lessons
learned from studies of families at risk for Huntington Disease,
a fully penetrant, incurable neurodegenerative disorder, have
limited applicability to issues of how women in the general
population, even those with a mother or sister with breast
14. See Bob Kuska, BRCA1 Discovery Aftermath: No Rush for Genetic Testing, 87 J.
NAT'L CANCER INST. 1578, 1578 (1995) (discussing the relatively small number of calls received
by the National Cancer Institute after the announcement of the BRCA1 gene and its link to cancer
in European Jews).
15. Gail Geller, Ph.D., Personal Communication (Aug. 1996).
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cancer, will respond to an offer of genetic testing for breast
cancer risk.
The purpose of this Article is to suggest a different frame-
work within which to think about these questions. We propose
that a cultural context, larger than genetic disease, needs to be
considered. Specifically, we will explore cultural attitudes
toward three issues which we believe comprise much of the
context into which genetic susceptibility testing for breast
cancer will emerge: (1) The cultural construction of cancer,
and, specifically, breast cancer as an illness; (2) attitudes of
potential test consumers toward medical information, including
genetic information, provided through technology; and (3) the
use of risk information within contemporary biomedicine for
prediction of future disease. We intend to show why the specif-
ic illness for which genetic testing is offered has a profound
effect on the degree of interest that testing evokes. Conversely,
we will demonstrate that genetic testing is a less novel enter-
prise than traditionally thought. Rather, it is a very logical
extension of the on-going trend to assess and quantify risk of
disease far in advance of the presentation of symptoms. The
Article is, therefore, divided into three sections, each focusing
on different parts of the phrase genetic testing for breast can-
cer risk.
Part I, which is the longest section, focuses on the disease
for which testing is offered. It discusses the social construction
of cancer and cancer phobia. It draws upon the historical work
of James T. Patterson to demonstrate the development of the
themes which define the relationship of the individual to cancer
risk in the United States today. It then examines the applica-
bility of these themes to contemporary images of breast cancer,
especially the way risk for breast cancer has been constructed
and is perceived by women in the United States today. Data for
this section come largely from an analysis of recent popular
literature undertaken by the authors.
Part II explores attitudes toward science in general and
genetic testing in particular. Preliminary data are presented on
the knowledge about, and attitudes toward, genetic susceptibili-
ty testing of potential test consumers. These data come from
interviews conducted with one hundred European-American
and African-American women recruited from the general popu-
[Vol. 7:135
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lation to represent varying levels of breast cancer risk and
socioeconomic background. 6
Part III specifically focuses on the concept of risk and risk
management within contemporary biomedicine. The purpose of
this section is to suggest how genetic testing fits within an
already existing trend within medicine for predicting and quan-
tifying distant risks of disease.
Finally, at the conclusion of this Article, we will return to
the issue of whether there is any reason to believe that any-
thing in Jewish culture is likely to outweigh the general cultur-
al forces we have discussed in predicting the demand for and
response to genetic susceptibility testing for 'breast cancer risk
by Ashkenazi-Jewish women.
I. THE SOCIAL CONSTRUCTION OF CANCER
PHOBIA
Medical anthropologists draw a distinction between the
concepts of disease and illness." The term disease is used to
demarcate and delimit those things which are commonly seen
in Western biomedicine as constituting the entirety of being
unwell - abnormalities in the structure and function of bodily
systems. Diseases can conceptually exist apart from the sick
person who is sick. In contrast, illness refers to the embodied
experience of disease. Particularly, illness encompasses the
physical sensations, the search for causes, cures, and meaning,
and the complex interaction of the experience of illness within
the web of interpersonal relationships and activities which
constitute daily life.
16. This research was funded as part of the Cancer Genetics Studies Consortium. It is a
qualitative study of the understandings and attitudes about health, breast cancer, and genetic
testing of women at varying risk for breast cancer. It includes women of varying socioeconomic
levels and four ethnic groups (African-American, European-American, Native-American, and
Ashkenazi-Jewish). See Wylie Burke, Genetic Testing for Breast Cancer Susceptibility (grant
proposal) (on file with author and the National Center for Human Genome Research of the
National Institutes of Health).
17. See ARTHUR KLEINMAN, THE ILLNESS NARRATIVES: SUFFERING, HEALING AND THE
HUMAN CONDITION 3-6 (1988) (defining illness and diseases as fundamentally different con-
cepts); Arthur Kleinman et al., Culture, Illness, and Care: Clinical Lessons from Anthropologic
and Cross-Cultural Research, 88 ANNALS INTERNAL MED. 251,251 (1978) (discussing concepts
derived from anthropologic and cross-cultural research which may provide an alternative
framework for identifying health care issues that require resolution).
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The usefulness of this distinction is that it forces us to
consider as problematic, and thus requiring examination and
explanation, issues which might not seem problematic if looked
at through a biomedical model of disease alone. For example,
this distinction leads us to consider which diseases are consid-
ered to bear the heaviest burdens by particular societies at spe-
cific times. Cancer is the quintessential feared illness in twenti-
eth century America. Since it is also a frequently fatal disease
for which attempted cures are often arduous, disfiguring, and
unpleasant, the fear surrounding it might appear to be a result
of the characteristics of the disease itself. Yet, once the distinc-
tion between disease and illness is embraced, the very intensity
of dread that cancer evokes, and the way it crowds from view
other common, often fatal, and equally debilitating diseases,
becomes problematic and demands a careful examination.
James T. Patterson, in his book, The Dread Disease: Can-
cer and American Culture,8 traces the history of cancer pho-
bia as a phenomenon that is distinct from the actual disease.
Patterson believes that while cancer had been long known and
feared, cancer phobia did not exist in the United States until
the end of the nineteenth century. His thesis states that the de-
velopment of cancer as the dread disease awaited the creation
of a prosperous business and professional class whose lives
were marked by a new longevity, comfort, and affluence. This
very comfort, according to Patterson, had the paradoxical effect
of leading to an increased fear of illness and, more particularly,
of early death. Although this was a time in which tuberculosis
was epidemic while cancer was not considered a particularly
common disease, tuberculosis was associated largely with
conditions of poverty. It was, therefore, somewhat predictable
in its occurrence and remote from the burgeoning middle class.
Cancer, on the other hand, was believed to often attack precise-
ly those whose lives were seen by some social critics as very
"comfortable" and overly "civilized."' 9 Thus, in addition to an
objective and reasonable fear of cancer, this illness may have
served a metaphoric function both as a symbol of the remain-
18. JAMES T. PATrERSON, THE DREAD DIsEAsE: CANCER AND MODERN AMERICAN
CULTURE (1987).
19. Id. at 31-33.
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ing kernel of risk within increasing safety, and of the distrust
with which a culture shaped by the Protestant Ethic viewed a
life of ease and luxury."
Several themes came to define the discourse of cancer
phobia in the first decades of the twentieth century and they
continue to be central in contemporary discussions of cancer.
We believe they have great relevance for potential consumer
interest in genetic susceptibility testing for breast cancer as
well. One of these themes was the belief that cancer rates
were increasing precipitously. Although countered by the same
scientific cautions that greet today's discussion of a breast
cancer "epidemic," cancer in the early part of the century was
described by the American Society for the Control of Can-
cer, as existing in epidemic proportions and being "a menace
to the welfare of mankind"22
Also of interest is the striking continuity between es-
poused causes of cancer then and now. Specifically criticized
were the "softness," excessive consumption, and "luxurious liv-
ing" of modem lifeY One writer proposed, in a theme which
would be commonly repeated, that cancer most frequently
afflicted "... . well-nourished persons who live well and do
not work off their waste products., 24 An improper, too gener-
ous diet was hypothesized again and again as causing the dis-
ease.' Yet, paradoxically, the stresses of contemporary, com-
petitive, industrial existence were also cited as a cause for
cancer's increase. Most intriguing in its prefiguring of today's
more psychologically minded era, was a view that not only
tension but, specifically, emotional repression could also lead
to cancer.26
It is worth noting that all of these criticisms, while aimed
globally at a changing and dangerous society, carry implicit
20. For a more in-depth discussion of this concept, refer to Susan Sontag, Illness as
Metaphor, in HEALTH AND DIsEAsE: A READER, 33, 33-37 (Basiro Davey et a]. eds., 1995)
(discussing the attitudes and metaphors associated with tuberculosis and cancer).
21. This organization later changed its name to the American Cancer Society. PATrERSON,
supra note 18, at 72.
22. Id. at 78-82.
23. Id. at 43.
24. Id. at 44.
25. See id. at 103.
26. See id. at 103.
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correctives which are the responsibility of the individual. Soci-
ety might be getting "soft," but individuals could eat different-
ly, live more in accord with the Protestant Ethic, and even lead
less emotionally repressed lives. This theme of individual re-
sponsibility for cancer prevention grew and strengthened
throughout the twentieth century.
One surprising viewpoint about cancer in the beginning of
this century has particular relevance to current attitudes toward
breast cancer. At the beginning of the century, when cancer of
internal organs often metastasized and led to death without a
specific diagnosis, and before the mass production and market-
ing of cigarettes made lung cancer common among men,2
7
women's breast and reproductive disease were the most fre-
quently diagnosed cancers. In fact, cancer was seen as a wom-
an's disease.28 Thus, when statistics first appeared which
demonstrated that cancer had increased among men, it was
suggested that this was another proof of the link between can-
cer and a soft, overly indulgent, contemporary life which was
now even making men vulnerable to a woman's disease.29 It
seems possible that this perceived link between cancer and
women may have contributed to the impression that cancer was
particularly private and especially shameful. It is also interest-
ing to note that the American Society for the Control of Cancer
used this perception of the special connection between women
and cancer to begin an auxiliary of prominent and wealthy
women who succeeded in raising both awareness in and money
for cancer. This was an interesting forerunner of the immensely
effective National Breast Cancer Coalition of today.
A. "The Magic Bullet" and "Early Detection"
The final thread of the cancer discourse, which can also be
traced back to the beginning of this century, involves the
search for a cure and the dogma of early detection. James T.
Patterson wrote that one aspect of the ethos of the new, grow-
27. See id at 203. See also ELIZABETH WHELAN, A SMOKING GUN: How THE TOBACCO
INDUSTRY GETs AWAY WITH MURDER 72-80 (1984) (relating the increased marketing and
production of cigarettes to the beginning of the investigation into the link with lung cancer).
28. See PATrERSON, supra note 18, at 43.
29. See id. at 43.
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ing middle class which so feared cancer was an optimistic
assumption that all problems could be solved. The middle class
also had extreme faith in "expert, scientific solutions."3 By
the middle of the twentieth century, this faith was spectacularly
rewarded as science and medicine provided a remarkable series
of successes. These successes ranged from the discovery of
antibiotics and vaccines, to air flight, and ultimately, to the
creation and use of "the bomb." Yet, despite these successes in
subduing nature through science, a cure for cancer remained
elusive. Although articles appeared in the popular press herald-
ing a "breakthrough" just around the comer, the repeated fiz-
zling of such hopeful rhetoric required a different approach to
"beating cancer." From the beginning of the century until now,
that approach has been the lifesaving potential of "early detec-
tion."
Although what the American Society for the Control of
Cancer saw as "early detection" when it began its public edu-
cation campaign in the 1920s would be considered detection at
a late disease stage now, the message that they presented has
changed very little if at all. From their very inception, the
American Society for the Control of Cancer emphasized that
individuals had to be vigilant for signs of cancer and had to get
medical attention immediately. This was a grave responsibility
to others, as well as to oneself. Thus, a public service adver-
tisement from 1921 depicted a widow and two small children
sitting sadly around a table reading an information brochure
under the heading "If Daddy had only known this!" Daddy, it is
clear, is gone because he did not follow the advice of the ad-
vertisement to "attack cancer the right way," by attending to
cancer's "warning signs," and by immediately seeking compe-
tent medical help.3' A 1932 advertisement exhorts the reader
to "Fight Cancer with Knowledge."32 Yet another advertise-
ment from the same year counsels, "Don't Fear Cancer, Fight
It." This particular advertisement, suggestive of the goddess
30. Id. at 71-74.
31. See id. at 77.
32. Id. at71-74.
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Athena holding up a sword, is strikingly reminiscent of the
current campaigns for breast cancer awareness. 33
Throughout the early twentieth century, methods of cancer
detection improved. By the 1970s it was possible to detect
some cancers at a largely asymptomatic stage. In an odd way,
this advance presented a new problem. No longer were people
being asked simply not to ignore obvious signs of potential
cancer; they were now being asked to go to a doctor on a
regular basis so that an occult disease might be detected. This
led to a new theme in the advertisements: mainly that feeling
well did not necessarily mean you were well. Thus, a 1970
American Cancer Society advertisement promoting regular
physical examinations, shows an ostrich with its head in the
sand and asks rhetorically, "If you're feeling great, why both-
er?" It answers that "[miany cancers are curable if detected
early .... An annual checkup helps your doctor... make
sure you are really as fine as you feel." The advertisement
ends by again stressing the personal level of responsibility in-
volved in fighting cancer with the line "It's up to you.. .". If
advertisements in the 1920s were sympathetic to the father who
simply did not know enough about cancer, in later periods,
more severe censure was attached to those who should have
known better, but chose to avoid the actions that could have
detected early disease.
Currently, the most common public service announcements
for early detection focus on mammography and reiterate the
theme of responsibility to self and others. In fact, all of the
general themes involved with cancer and cancer phobia dis-
cussed above coalesce in the fight against what has become the
quintessential cancer, and most women's ultimate dread dis-
ease, breast cancer.
B. Deconstructing Breast Cancer
One of the assumptions underlying our research is that
women's beliefs and attitudes about breast cancer will strongly
shape their actions in regard to genetic susceptibility testing.
Breast cancer today is a major source of story lines for wom-
33. Seeid.at 77.
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en's and general news magazines. Therefore, in order to find
out what images of breast cancer might be shaping the under-
standings and opinions of the women we were interviewing, we
began an analysis of the current coverage of breast cancer in
popular literature. Our preliminary effort consisted of a single
search on the word "breast cancer" in the General Periodicals
Index in the Seattle Public Library. We confined this initial
search to three years. This period, 1993-1995, included the year
when the BRCA1 gene was sequenced.
Our first finding was that the number of articles discussing
breast cancer appeared to increase steadily throughout the
period. In 1993, we located thirty-one articles; we located fifty
in 1994; and in 1995, we located sixty-four. 4 More striking
than the increasing number of articles that we located was the
tone and emphasis of the articles, in particular, how this tone
reflected the elements of the cancer phobia discussed above.
The primary themes apparent in these articles were the follow-
ing: the presentation of breast cancer as a particularly dreaded
disease of epidemic proportions; and, breast cancer as a disease
largely attributable to various elements of modem lifestyle. A
new theme, but one prefigured by Patterson's discussion of the
genesis of cancer phobia, was of breast cancer as a disease of
affluent, professional, and young women.
Breast cancer is presented in these articles as vividly
frightening. Typical of the tone are the following headlines:
"The Terrifying Statistic - That One in Nine Women Will
Get Breast Cancer... ."How Safe Are Your Breasts?," and,
"Cancer Stalks the Women in Anna Fisher's Family .... " 35
We found that articles frequently used the familiar one in nine,
or one in eight, breast cancer risk number, but very rarely
clarified that this number is only relevant to women who live
well into their eighties or nineties. Often stories begin with an
alarming array of statistics to support a claim of epidemic
34. These articles and the numerical analysis are on file with the author.
35. Surviving Breast Cancer: Seven Extraordinary Women Talk About Going On,
MCCALLS, Oct. 1993, at 110 (illustrating that frightening statistics can be misleading); Malcolm
Gladwell, How Safe Are Your Breasts?, NEw REPUBLIC, OcL 24, 1994, at 22 (discussing how the
revised guidelines for a mammography may be more cost-conscious than health-conscious); Larry
Thompson, The Breast Cancer Gene: A Woman's Dilemma, TIME, Jan. 17,1994, at 52 (discussing
the fear provoked in one woman by her family's history of breast cancer).
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incidence and increase in breast cancer. In some articles, the
tone made it seem as though getting breast cancer were inevi-
table. For example, a story in Vogue, a leading women's
magazine, begins with these poignant sentences: "Throughout
the ages, the breast has been associated with beauty, sensuality,
and fecundity. But today when we think of the breast, we think
of cancer."36 This sentiment is particularly striking since
words like these appear in a number of our preliminary inter-
views with young, professional women who repeatedly describe
their breasts as "time bombs." We would argue that the articles
found in popular literature, such as this one in Vogue, create,
as well as reflect, the atmosphere of fear and desperation
which some women today feel about their risk for this disease.
As in the past, the only hope offered by many of these
articles is personal vigilance which leads to early detection;
such vigilance continues to be presented as not only an oppor-
tunity, but also as a responsibility. However, the standards of
what constitutes vigilance have become much stricter than they
were in the past. Thus, an abstract for an article in Redbook
magazine reads: "A woman describes how she reacted when
she discovered a lump in her breast .... She went into denial
and delayed seeing a doctor. . . ." Yet, a careful reading of the
article reveals that she "delayed" seeking medical advice from
Saturday afternoon until "late Monday morning!"
C. "I am Stunned... I Have No Risk Factors"
Another aspect of the paradigm of vigilance, and one
which can be expected to have great significance for women's
response to the availability of genetic testing for cancer suscep-
tibility, has to do with the elaboration of "risk factors" in the
scientific literature and the popular press. The theme of delin-
eating "your risk factors" for breast cancer was an extremely
common one in the articles we collected. Breast cancer risk
factors mentioned in these articles include the following: fami-
ly history of breast cancer; reproductive history including age
at menarche and menopause, age at first pregnancy, and breast
36. Noelle Oxenhandler, Fruits of the Body, VOoUE, June 1995, at 56 (describing the
paradox of different views of the breast and the effect of breast cancer on those views).
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feeding practices, as well as spontaneous and induced abortion;
elements of "life style" such as diet, especially fat and alcohol
intake, lack of physical exercise, and stress; and finally, an
astonishing array of other potential risks including being single,
having a mother who was older than average when you were
born, the use of electric blankets, being of above average
height, and being highly educated.
The usefulness of knowing about a risk factor like height,
about which nothing can be done, or educational level, which
of logical necessity must be merely a marker for something
else, is highly questionable. It raises an issue of why it seems
necessary to report every epidemiological risk association as
though it is a factor relevant to the lives and practices of in-
dividual women. We would suggest that there are two implicit
assumptions that underlie this relentless delineation of risk fac-
tors. The first is a view that the risk of breast cancer is so high
that almost anything that could be done by a woman should be
done. The second is a belief that the obverse of anything that
creates risk can reduce risk. Thus, if a high-fat diet increases
risk, women can and should eat a low-fat diet to protect them-
selves. So fervent is this belief among some scientists that one
recent book, written by a physician, actually promises that
eating a low-fat diet will "save" you from breast cancer.37 Or,
if late age at childbearing increases risk, then teenage preg-
nancy can be protective and should be undertaken, as one
prominent woman scientist recently recommended." To a
large extent, however, information is such an undisputed good
in U.S. culture 9 that little overt justification seems necessary
to keep women informed about even the most speculative
breast cancer risk findings. We believe that this discourse of
risk factors will help pave the way for an acceptance of genetic
37. See ROBERT M. KRADJIAN, SAVE YOURSELF FROM BREAST CANCER 85 (1994).
38. See Maureen Henderson, Current Approaches to Breast Cancer Prevention, 259
ScIENCE 630, 631 (1993) (considering the viability of social and health policies that encourage
and support younger women to bear children to prevent breast cancer).
39. See Nancy Press et al., Why Women Say Yes to Prenatal Screening, Soc. SCi. & MED.
(forthcoming 1996); C.H. Browner & Nancy Press, The Production ofAuthoritative Knowledge in
American Prenatal Care, 10 MED. ANTHROPOLOGY Q. 141, 153 (1996) (describing the concept of
authoritative knowledge and reviewing study results, which explore the role of individual patients
in facilitating the dominance of biomedical authoritative knowledge).
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information, which is perhaps the most powerful risk informa-
tion of all.
Despite the very broad range of risk factors discussed in
these articles, there is one kind of woman who appears in these
magazines to be especially at risk - the young woman. Ap-
proximately one-third of the articles we analyzed used a per-
sonal vignette to focus or anchor the story. This is a common
journalistic technique and, therefore, it is not particularly sur-
prising to find it employed so frequently. Nevertheless, we
believe that these stories are particularly effective in making
breast cancer seem like every (young) woman's problem.
Indeed, stories often focus on young women who state that
they never expected this to happen to them. These women
often are presented as being caught especially unaware and
vulnerable. Thus, a young woman whose breast cancer is diag-
nosed during a routine mammogram begins her personal story
with the following words: "I am stunned. There must be a
mistake. I have no risk factors. Maybe my name was mistak-
enly placed on someone else's mammogram. I can't stay here
anyway, my parking meter is about to expire. And I have a
luncheon appointment."' But so many stories begin in this
same way, with a shocked, baffled woman who has had the
mundane dailiness of her life torn apart, so sentences about
how sunny and happy things were before function like the
sinister music in a horror movie: One suspects that the savvy
reader is supposed to respond, "How could you not have ex-
pected this?"
In fact, in one of the most instructive of these personal
vignette stories, the woman explicitly expresses the idea that
her false sense of security may have somehow been connected
to the bad outcome of finding a breast lump. It is entitled, "I
thought I couldn't get breast cancer at 31. Then I found a
lump!"
I knew the moment I felt it. I knew .... [and] my mind auto-
matically registered the awful inevitability of what lay ahead.
Breast cancer .... surgery .... chemotherapy .... hair
40. Robbie Lyons, It's Probably Nothing, This Lump in My Breast, But..... GOOD
HOUSEKEEPING, Mar. 1993, at 58 (tracing the author's emotional reactions from the time her
mammogram revealed a lump through the time she received a mastectomy).
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loss .... death. I couldn't believe it .... [h]alf praying, half
pleading, I asked it to go away, suddenly filled with remorse. I
wanted to say I was sorry. To somehow make things right. I
kept thinking that maybe this was some sort of divine punish-
ment for being such a frivolous person. Because just a minute
ago, the only thing I had been worrying about was my tan
lines.4'
One of the most striking aspects of this story is that it is
revealed, although not until the final paragraph, that this wom-
an did not have breast cancer. Rather, she was diagnosed with
a benign breast lump. The first person narrative presents this as
a miraculous reprieve. Because of the tone the woman takes,
the moral of the story is not that in the future she (and by
extension other women her age) should check, but not panic
about breast lumps. Rather, she is somehow chastened; she can
no longer hide in a world of parties and tan lines. She now
gives generously to her hospital's cancer drive as though she
must be thankful to medicine itself for saving her. What makes
this article particularly worrisome from a public health view-
point is that, although for this thirty-one year old, the likeli-
hood that a breast lump will be benign is overwhelming, the
story does not provide any statistical framework so that the
reader can understand that this woman's extreme degree of
distress was, if understandable, nevertheless unnecessary.
The fact that this woman was thirty-one is also representa-
tive of the universe of these media presentations of breast
cancer. Glamour magazine, whose readership hovers in the
eighteen to twenty-five year old range, has had two cover
stories on breast cancer in the past thirteen months. It is worth
wondering why it seemed appropriate to the editors to run two
major stories on this topic within a year of each other given
the age of their readership. Nevertheless, one of the stories is
based on a personal vignette. It is about a friendship between
two women, one with now-metastasized breast cancer. The
picture of the two of them together show that they are both
wrenchingly young; the article informs us that the woman with
breast cancer was diagnosed, six weeks before her wedding, at
41. Jennet Conant, "Not Me!" REDBOOK, June 1993, at 96 (relating the author's personal
reaction to her discovery of a lump on her breast).
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the age of thirty-one.42 It is almost as though this article is
creating a universe in which the thirty-one year old woman
from the Redbook article is living in a world in which one
should expect breast cancer at this age.43
In aggregate terms, we found twenty newspaper and maga-
zine articles in 1994 which used personal vignettes and gave
the ages of the women profiled. Of these, sixteen described
women diagnosed with breast cancer between the ages of twen-
ty-nine and thirty-nine. Of the remaining four stories, only one
was about a woman over fifty. She was, in fact, precisely fifty,
the oldest woman in the group. Thus, if you live in the world
of these stories and you are diagnosed with breast cancer you
have an eighty percent chance of being in your twenties or
thirties. In reality, the chances of a woman developing breast
cancer by the time she is thirty-one is less than two in one
thousand.' Likewise, the modal age of a breast cancer diag-
nosis is sixty-four.
The fact that women are hearing and believing these mes-
sage is supported by a variety of findings. One is the percep-
tion of clinicians, such as prominent breast surgeon, Susan
Love, who observes that the women who are expressing the
most interest in mammography are educated women under age
fifty.45 This occurs despite the fact that the usefulness of
mammography for this age group is unproven. Research sup-
ports her impression. In one study, European-American women
age forty to forty-nine were actually more likely than older
women to undergo regular mammographic screening.'
Additional support for the view that breast cancer is be-
coming regarded as a young woman's disease comes from a
survey conducted by one of the authors with 450 Californian
42. Kate Manning & Wendy Morse, Wendy has Breast Cancer. Kate Doesn't. The Story
of Two Friends, GLAMOUR, Aug. 1996, at 186.
43. See supra footnote 41 and accompanying text.
44. See Eric J. Feuer et al., The Lifetime Risk of Developing Breast Cancer, 85 J. NAT'L
CANCER INsT. 892, 894 (1993) (citing statistical evidence for the probability of developing
invasive breast cancer for various age groups).
45. Susan Love, Personal Communication (June 1996).
46. See John P. Fulton et al., Determinants of Breast Cancer Screening Among Inner-City
Hispanic Women in Comparison With Other Inner-City Women, 110 PUB. HEALTH REPORT 476,
478 (documenting the differences between Hispanic and white and black Non-Hispanic women in
obtaining screening breast examinations and mammograms).
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women of diverse ethnic backgrounds.' When asked to indi-
cate what they thought was the most common age for women
to develop breast cancer, more than ninety-five percent incor-
rectly chose under sixty, and three-quarters felt that younger
than fifty was the most common age to get breast cancer.
In sum, we have women, especially young, educated wom-
en, who are terrified of breast cancer and overestimate their
own vulnerability to the disease. Their sense of risk is created
and reinforced by media presentations of breast cancer which
also accustom them to thinking in terms of "risk factors."
Since many of the most frightened women also may be those
with the best access to health care services, we would suggest
that a highly motivated set of consumers exists for anything
which they believe may reduce their risk of breast cancer. The
question that we will turn to now is whether we have any
reason to believe that these women will think that genetic
susceptibility testing will, in fact, help them with risk reduc-
tion.
II. GENETIC TESTING - ANGER AT
SCIENTISTS/FAITH IN SCIENCE
In the late 1940s and 1950s, Americans firmly believed that
the science which had split the atom and made "the bomb"
could certainly cure the problem of cancer.' However, after
close to 150 years of journalistic reports of cancer "break-
throughs" about to occur, the contemporary versions of this
faith in science evidence somewhat more frustration. Thus, the
frequently heard phrase, "if they can put a man on the moon,
then why can't they find a cure for cancer?" Our interviews
also uncovered a skepticism about certain aspects of science.
The most succinct expression of this was a phrase used with
surprising regularity by women from families at high-risk for
breast cancer: "If men got this disease there'd be a cure by
now." Yet, what is most interesting about this statement is not
the explicit anger expressed toward the scientific establishment,
47. See Nancy Press, Survey Conducted for the California State Breast Cancer Early Detec-
tion Partnership Program (BCEDP), Orange County Region 10 (1995) (on file with the State of
California and author).
48. See PATrERSON, supra note 18, at 140.
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which is believed to be underfunding research on women's
health issues, nor at scientists, who are accused, in essence of
just not doing their job, but the implicit, and unshaken, faith
expressed in the scientific enterprise itself: If only scientists
cared enough and targeted the right issues there would be a
cure. This underlying faith in science was evident in the mag-
azine articles we analyzed as well. Even those which reported
contradictory scientific findings, continued to respectfully cite
an array of scientific experts under headlines such as: "What
Doctors Wish You Knew About Breast Cancer" and "If
You're Under 40, These New [Scientific] Facts Could Save
Your Life."'49 While American women clearly express fatigue
at waiting for the "magic bullet" of a cure, cancer remains
now, as James Patterson saw it to be in the late nineteenth cen-
tury, a social, and ultimately a political, "problem" to be
solved. Science was the place to look for that solution in the
past, and it apparently still is. In fact, what may be the clearest
and most public expression of this tension between anger at
scientists and faith in science is perfectly expressed in the
official slogan of the highly influential National Breast Cancer
Coalition: "Breast Cancer. Say It. Fight It. Cure It. Damn It."
Given this enthusiasm about science and scientific find-
ings, we were surprised by the small number of articles which
discussed the discovery of BRCA1. Based on this lack of cov-
erage, however, it is perhaps not surprising that only a small
proportion of the women we interviewed were knowledgeable
about this topic. Only about one-third recognized the term
BRCA1 or the phrase "a breast cancer gene." Of that third,
only half could actually produce any information on this topic.
It is interesting to note that there was no statistically significant
difference in the knowledge base of women with or without a
family history of breast cancer.
Participants' interest in testing was assessed through a
series of seven-point Likert scales. Each scale was a response
to a question which always began the same way: "Imagine that
your doctor asked you if you wanted to take a genetic test for
49. Linda Heller, What Doctors Wish You Knew About Breast Cancer, REDHOOK, Apr.
1993, at 38 (quoting statistics from the National Cancer Institute to clarify misconceptions about
the risk of cancer).
[Vol. 7:135
ANTHROPOLOGICAL PERSPECTIVES
breast cancer risk and you said to the doctor, 'I don't know if
I want it; let's say I took the test and .... "' The end of the
sentence was varied fourteen times, each time with a change in
some essential feature of the test. For example, one question
suggested that a positive test result would mean that the risk of
developing breast cancer was fifty percent, while another ques-
tion asked if the woman's interest would be different if a posi-
tive result meant a ninety percent chance of breast cancer.
Other questions assessed interest in testing given the existence
of different possible interventions, such as prophylactic sur-
gery, gene therapy, or just the existing regimen of early detec-
tion. Participants were asked to indicate their degree of interest
on the Likert scale, as well as to explain their thought process
with regard to each answer. The purpose of these scales was to
see what types of uncertainty women found most troubling and
to expose women to the idea that this test would present many
complexities.
Below are the results from our first one hundred partici-
pants from the first and the last questions asked to assess hypo-
thetical interest in testing. The first question was intended to
establish a baseline level of interest predicated only on the
small amount of information we had imparted, plus whatever
underlying assumptions the participant might have had about
the usefulness of medical tests in general. The final question
asked women for an overall, gut-level assessment of their in-
terest in testing now that they had completed all the scales and
had had the opportunity to learn and think about the test.
Therefore, to the greatest degree possible, these could be con-
sidered "before-thought" and "after-thought" responses.
In answer to the first question, over seventy-seven percent
of our participants indicated they would want to take such a
test. There was no significant difference between the respons-
es of women with and without a family history of breast can-
cer. Thus, it would appear that neither a great deal of knowl-
edge, nor even much exposure to information about genetic
susceptibility testing for breast cancer is necessary in order for
'women, hypothetically, to accept an offer of testing. Even
more interesting, however, is our finding that following thirteen
more Likert scales and much discussion of what a test might or
might not be able to do, an almost identical percentage of par-
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ticipants (seventy-seven percent) indicated that they were still
somewhat likely to definitely interested in testing.
One of the most interesting explanations women gave for
their interest in testing came in response to out Likert scale
about prophylactic mastectomy. The idea of mastectomy to
avoid disease appeared repellent and even bizarre to many
women. Yet, many of those who rejected this opinion still
professed a strong desire to take the test in response to this
specific Likert scale. The most common explanation given was
that just knowing about their increased risk would be helpful
because it would motivate them to be more vigilant about early
detection and make lifestyle modifications, especially consum-
ing a lower-fat diet and increasing exercise.
Further, detailed analysis of these data is necessary to be
certain of the meaning of these results. It would appear, how-
ever, that women's belief in the value of a medical test offered
by their physician is extremely robust. Such a result would be
in keeping with findings from research on the routinization of
other medical technologies which involve little physical risk
and can be seen as part of standard medical care. That such
easy routinization can take place even when bioethicists or
other social theorists see significant ethical dilemmas in a
technology is borne out by the rapid routinization of prenatal
screenings, such as maternal serum alpha-fetoprotein blood
screening for neural tube defects." These data would also
suggest that unless some very specific and in-depth educational
efforts accompany an offer of testing, women are not likely to
see this testing in the way bioethicists do -- as a new order of
medical tests replete with scientific uncertainty and bioethical
conundrums. Indeed, susceptibility testing for breast cancer
will be viewed under a rubric that is already well-established in
medicine -- fairly "simple tests that tell you about your future
risks."
50. See Nancy Press & C.H. Browner, 'Collective Fictions': Similarities in Reasons for
Accepting Maternal Serum Alpha-Fetoprotein Screening among Women of Diverse Ethnic and
Social Class Backgrounds, 8 FErAL DIAGNOSIS & THERAPY 97, 105 (1993) (analyzing the
decisions of a diverse group of women and what factors affected their decisions to accept or refuse
a prenatal test); Nancy Press et al., Why Women Say Yes to Prenatal Screening, Soc. SCI. & MED.
(forthcoming 1996).
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IM. BEING "AT-RISK" - THE PURPOSE OF
PROPHECY
Sociologists, such as Leo Baric and, more recently, Regina
Kenen, have discussed the creation of a new social role for pa-
tients: that of being "at-risk" for disease rather than actively
sick." But this new social role is dependent upon prior chang-
es in biomedicine. Figure 1 below is a representation of this
conceptual and historical change within biomedicine in the
United States as it affects the distance between symptom and
diagnosis.
The Historical and Conceptual Progression from Diagnostic to Predictive Testing
Se enlna GenefleTestiny
4in asymptomatic
12amosls individuals
in asymptoatic
individuals
II kd, aiu.I o f o,.,doo nsb ron
51. See Leo Baric, Recognition of the "At-Risk" Role: A Means to Influence Health
Behaviour, 12 INr'L J. HEALTH EDUC. 24, 31-32 (1969) (describing a system within which an
individual moves while experiencing different degrees of health or illness); Regina H. Kene, The
At-Risk Health Status and Technology: A Diagnostic Invitation and the 'Gift' of Knowing, 42
Soc. Sci. & MED. 1545, 1545 (1996) (identifying the creation of the at-risk health status along
with possible risks of the status and the need for standards).
HEALTH MATRIX
Movement along this continuum of risk from left to right
can be conceptualized as a change both in the relationship of
patient to physician and as a change in the role of biomedicine
itself. At the left end of the continuum, a patient initiates con-
tact with a physician following the appearance of symptoms
that cause discomfort or interfere with daily functioning. As
one moves toward the right, the patient goes to the physician,
sometimes in response to a "warning sign" of disease, such as
a painless breast lump, and sometimes simply for a periodic
examination. In each case, the patient feels well, but has the
possibility of being told that some disease exists. As one
continues toward the right along the continuum, less is known
about the natural history of the disease detected or the efficacy,
or even necessity, of medical interventions. It is not yet known,
for example, how much latent prostate cancer would ever prog-
ress to life-threatening disease.52 Thus, it is difficult to work
the equation which balances iatrogenic harm and needless
anxiety against reduction in morbidity and mortality. Further
still to the right, yet conceptually prior to actual genetic testing,
a patient can be classified according to risk of disease on the
basis of family history. Although the risk prediction is very
imperfect, such classification raises the issue that a person
without any disease may, because of a risk classification, begin
to consider him or herself not quite well. These are the stages
which have set the background for genetic testing. Represent-
ed at the furthest right pole of the continuum, genetic testing
presents a situation in which an individual, or even a fetus, can
undergo a "simple blood test," and be given a specific number
which indicates their quantitative risk for a disease which may
not occur until decades in the future.
Our purpose in proposing this framework is not to debate
the usefulness of a preventive health paradigm in reducing
morbidity and mortality in various situations. Rather, we are
interested in presenting the idea that there is a cultural belief
52. See Barnett S. Kramer et al., Prostrate Cancer Screening: What We Know and What
We Need to Know, 119 ANNALS INTERNAL MED. 914, 918 (1993) (critically evaluating evidence
for the implementation of screening of asymptomatic men for prostate cancer using the prostate-
specific antigen (PSA) blood test).
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which, distinct from advances in science, drives the constant
expansion of this continuum in the direction of future disease
prediction. We suggest that there is an implicit belief in the
contemporary United States that a probability statistic, accu-
rately calculated and named, can eliminate its own most essen-
tial element - uncertainty. This belief makes Americans see
risk information as inherently useful and may be one of the
reasons there is often insufficient attention paid to gaps be-
tween diagnostic sophistication and treatment options. This is
particularly relevant in the case of genetic susceptibility testing
for breast cancer because this belief may drive both clinicians
and test consumers to opt for genetic testing even in the ab-
sence of proven efficacy of treatment sequelae. To support this
point we would like to present data related to the current use
of risk calculations for breast cancer.
There are several models which are used to estimate a
woman's risk for developing breast cancer. Each one uses a
somewhat different set of factors in its calculations. 3 The
model created by Stephen Taplin, et al. is of particular interest
for the way it illuminates issues in the use of risk calcula-
tions.54
Stephen Taplin, et al. establishes four levels of risk for
women aged forty and over. Risk factors calculated in this
model include personal and family history of breast cancer, and
"minor risk factors" which refer primarily to hormonal and re-
productive history. The model also implicitly includes age as a
risk factor, since a woman over fifty can be assigned to a par-
ticular risk level with a smaller number of risk factors than can
a woman under fifty.
53. See Mitchell H. Gail et al., Projecting Individualized Probabilities of Developing
Breast Cancer for White Females Who Are Being Examined Annually, 81 J. NAT'L CANCER INST.
1879, 1880-82 (describing a relative risk model for predicting the probability of breast cancer);
Elizabeth B. Claus et al., Autosomal Dominant Inheritance of Early-Onset Breast Cancer:
Implications for Risk Prediction, 73 CANcER 643, 643 (1994) (describing a study which provides
age-specific risk estimates for women with family histories of breast cancer); Stephen H. Taplin et
al., Revisions in the Risk-Based Breast Cancer Screening Program at Group Health Cooperative,
66 CANCER 812, 812 (1990) (describing one health maintenance organization's development of a
risk-based selective approach to recommending cancer screenings).
54. Taplin et al., supra note 53, at 813 (identifying the strengths and limitations of the risk
classification system).
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TABLE 1
Risk Category Risk Factors Relative Risk
Women 40-49 Women 50+
Level 1 Prior breast Same 4-14
(highest) cancer, two
first degree
relatives
with breast
cancer
Level 2 One first- One first 1.9 - 3.5
degree degree
relative with relative or
breast cancer two minor
risk factors*
Level 3 One or more All other 1.2 - 1.9
minor risk women
factors*
Level 4 All other Not 1.0
(lowest) women applicable
* Minor risk factors: Second degree relative with breast cancer, early menarche
(age 10), late menopause (age 5), first birth after age 30 or nulliparity, previous
breast biopsy for benign disease.
The highest risk category, Level I, contains women with
personal or significant family history of breast cancer. These
women are calculated to have a relative risk of breast cancer
four to fourteen times greater than the average woman. Level
II contains those women with less marked family histories of
breast cancer; women over fifty can be assigned to this level if
they have two or more minor risk factors alone. This level is
considered to be associated with a relative breast cancer risk of
1.9 to 3.5 years. Women under fifty with one or more minor
risk factors are assigned to Level III, as are all remaining
women over fifty; the relative risk of breast cancer at this level
is calculated to be 1.2 to 1.9. This leaves Level IV, the lowest
risk level. In this risk model only women under fifty are con-
sidered to have a relative risk of 1.
The most interesting aspect of this careful, if somewhat
controversial, model is that it was devised specifically to aid in
establishing clinical practice guidelines for breast cancer
screening. It is therefore stunning to note that there are no
differences between risk Levels III and IV in terms of the
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recommended mammography screening guidelines. What then
is the purpose of distinguishing Level III from Level IV?
Level III is the level of "minor risk" factors. It contains
many of the factors discussed in women's magazine articles
on breast cancer. While geneticists probably would not consid-
er a relative risk of 1.2 to 1.9 particularly significant, the reac-
tion to reported risks in exactly this range among the women
we have interviewed suggest that they do find it significant,
and worrisome. When even a model intended to guide clinical
practice cannot distinguish interventions according to all the
risk levels delineated, it strongly suggests that there are ques-
tionable, but unquestioned, assumptions underlying the
elaboration of risk.
It is not possible to know to what extent health care orga-
nizations or providers in private practice are using these sorts
of risk calculations. Further, there are no data on how frequent-
ly women who are patients in such practices are being told
about their risk status. We suspect, however, that both of these
trends are increasing. An indication of just how widespread
such an approach may become was recently found in an an-
nouncement on the Internet. An insurance company in New
York State is offering a 1-800 phone number for women to
call. Women can use the telephone keypad to respond to com-
puter-generated questions about various risk factors and imme-
diately receive their breast cancer risk number plus follow-up
written information on "risk management."55 However, as we
have seen, the parsing of risk that is possible has far out-
stripped the targeting of interventions, or even the demonstra-
ble efficacy of those interventions that are available. Thus, it is
completely unclear whether enhanced "risk management" can
possibly occur. What seems likely, however, is that this road
will be the one more traveled, since it began long before the
advent of genetic susceptibility testing for breast cancer.
55. Anne Leininger, genetic counselor, Personal Communication (July 8, 1996).
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IV. CONCLUSION
To return to the original question, we can ask whether
Ashkenazi-Jewish women are more susceptible than others to
the lure of the sort of risk information genetic susceptibility
testing will provide. Perhaps some of them will be. But we
would suggest that this difference is likely to be marginal
because the forces that converge around BRCA1 testing are
likely to be so powerful for many women. These forces include
the following: (1) the construction of cancer as an especially
dread disease; (2) the feeling of extreme vulnerability to breast
cancer that many American women have, especially those with
the most access to cutting-edge medical services; (3) the fact
that the popular media have accustomed women to thinking
about risk and risk factors for disease; (4) the general move-
ment of medicine in the direction of prediction of future risk;
and, finally (5) the cultural belief that risk named is risk that
can be averted. Thus, it seems possible that Ashkenazi-Jewish
women may become the first group who, believing like most
other Americans, that knowledge is power and that all informa-
tion is knowledge, will trustingly hold out their arms for a
blood test while asking rhetorically, "how can it hurt to
know?" Sadly, the way that Jewish women may be different
from all other women is simply that they will be the first to
find the answers to this question. The problem, then, is not that
Ashkenazi-Jewish women are different from all other American
women. The problem is that they are probably not.
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